Search results for "Statines"

showing 3 items of 3 documents

Analysis and modulation of the inflammatory response through lung agression related to bacterial infection and mechanical ventilation

2015

Despite major advances since decades in the management of ventilated patients, ventilator-associated pneumonia (VAP) continues to complicate the course of approximately 28% of the patients receiving mechanical ventilation (MV). Among patients hospitalized in intensive care units, the risk of pneumonia is 3- to 10- fold increased in MV patients. However, MV is often the only way to care for critically ill patients with respiratory failure. It has now been clearly demonstrated that MV, in particular adverse ventilatory strategies could activate lung cells, thus leading to a proinflammatory response, even in the absence of pathogen. This is the biotrauma paradigm, which accounts, at least in p…

InflammationVentilation mécaniqueLésions pulmonairesStatinsPneumonie acquise sous ventilation mécaniquePneumonia[SDV.BC]Life Sciences [q-bio]/Cellular BiologyLung injuryStatinesProne positionMechanical ventilationDécubitus ventralAlarminesPneumonieAlarminsVentilator-associated pneumoniaInfection[SDV.BC] Life Sciences [q-bio]/Cellular Biology
researchProduct

The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice

2014

Reducing low-density lipoprotein cholesterol (LDL-C) levels using statins is associated with significant reductions in cardiovascular (CV) events in a wide range of patient populations. Although statins are generally considered to be safe, recent studies suggest they are associated with an increased risk of developing Type 2 diabetes (T2D). This led the US Food and Drug Administration (FDA) to change their labelling requirements for statins to include a warning about the possibility of increased blood sugar and HbA1c levels and the European Medicines Agency (EMA) to issue guidance on a small increased risk of T2D with the statin class. This review examines the evidence leading to these clai…

MaleSettore MED/09 - Medicina Internaendocrine system diseasesHSM MEDHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsAnticholesteremic Agents/adverse effectsMedizin1567-5688ComorbidityType 2 diabetesPharmacologyDiabeteHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosageCardiovascularFasting/bloodCohort StudiesRisk FactorsAnticholesteremic Agents/administration & dosageDiabetes Mellitus Type 2/prevention & controlMulticenter Studies as TopicMedicineT2DDiabetisAnticholesteremic AgentsDiabetesHemoglobin A Glycosylated/analysisFastingGeneral MedicineMiddle AgedDiabetogenicityCVDClinical PracticeObservational Studies as TopicCholesterol LDL/bloodCardiovascular DiseasesPractice Guidelines as Topiclipids (amino acids peptides and proteins)Disease SusceptibilityCardiology and Cardiovascular MedicineRisk assessmentCardiovascular Diseases/prevention & controlCohort studyAdultmedicine.medical_specialtyStatinHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic usemedicine.drug_classAnticholesteremic Agents/therapeutic useHydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacologyDiabetes Mellitus Type 2/etiologyRisk AssessmentMulticenter Studies as Topic/statistics & numerical dataPrediabetic StateMeta-Analysis as TopicDiabetes mellitusInternal MedicineHumansIntensive care medicinePrediabetic State/epidemiologyGlycated HemoglobinStatins; Diabetes; Diabetogenicity; T2D; Cardiovascular; CVDbusiness.industryCardiovascular Diseases/epidemiologyStatinsStatinnutritional and metabolic diseasesCholesterol LDLmedicine.diseaseComorbidityAnticholesteremic Agents/pharmacologyDiabetes Mellitus Type 2/epidemiologyDiabetes Mellitus Type 2Estatines (Medicaments cardiovasculars)Observational Studies as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessObservational Study as TopicForecasting
researchProduct

Study of leurocyte telomere lenght and transcription in patients in the acute phase of myocardial infarction

2011

Atherosclerosis with cardiovascular complications remains today one of the leading causes of death in developed countries. In this context, development of new biomarkers of atherosclerosis has an important place. Objectives of these biomarkers are: • to identify populations most at risk of developing cardiovascular complications, • to stratify patient groups to optimize their clinical management and therapeutic, • to reveal new therapeutic targets in the treatment of the disease. In this context, we identified three biomarkers of interest, leukocyte telomere length (LTL) and level of expression of leukocyte genes c-Fos (involved in inflammatory processes and oxidative) and OGG1 (necessary r…

Bio-marqueursLongueur des télomères leucocytairesInflammationPathologies athéromateuses[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyC-FosTabacStress oxydatifNo english keywordsInfarctus du myocardeOGG1Statines
researchProduct